In HER2+ colorectal cancer, anti-HER2 therapy may be less toxic alternative
Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...
EurekAlert!13d
In HER2+ colorectal cancer, anti-HER2 therapy may be less toxic alternative
In the SWOG S1613 clinical trial comparing this standard therapy to treatment with two HER2 inhibitors, these patients saw a similar level of clinical benefit, with lower toxicity, from the ...
Endocrinology Advisor1d
Enhertu Approved for HR+, HER2-Low/Ultralow Metastatic Breast Cancer
Enhertu (fam-trastuzumab deruxtecan-nxki) has received FDA approval for HR-positive, HER2-low, HER2-ultralow metastatic breast cancer.
Anti-HER2 Bispecific ADC JSKN003 Received Approval to Initiate a Phase III Clinical Study for the Treatment of HER2-positive Breast Cancer
Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has ...
Targeted Oncology11d
Elacestrant Shows Greater Benefit in Endocrine-Sensitive Breast Cancer
Paolo Tarantino, MD, PhD, discusses the approval of the oral therapy elacestrant for patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer with ESR1 mutations.
Cure Today11d
Itovebi-Based Treatment Has OS Benefit in PIK3CA+ HR+/HER2– Breast Cancer
Among patients with advanced PIK3CA-mutated, HR-positive/HER2-negative breast cancer, Itovebi-based treatment generated ...
PharmiWeb13d
Enhertu approved in the US as first HER2-directed…
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, ...